Leveraged buyouts, growth capital, angel investments, and seed funding—these private transactions take place, largely out of the public’s eye, not only in Connecticut or Silicon Valley, but also in Beijing, Shenzhen, and Shanghai.
In 2016, China’s private equity (PE) and venture capital (VC) firms raised over $70 billion, more than 20% of total such funding globally. At the same time, these firms also deployed capital to the tune of $223 billion, accounting for more than 70% of global PE/VC investments.
As late comers, these Chinese firms have rapidly grown into formidable financiers. Most Chinese PE firms are particularly interested in products and services that can be commercialized and scaled up quickly in China. They tend to invest in areas that align with China’s shift to a more consumer-driven economy. Meanwhile, Chinese VCs have been active players globally, particularly in Silicon Valley. They have focused on areas such as artificial intelligence, Internet of Things, and electric vehicles.
Trustbridge Partners, founded in 2006, has $5 billion assets under management from university endowments, pension funds, and strategic industry partners. Maintaining offices in Shanghai, Hong Kong, and Boston, the firm specializes in long-term growth investments in the technology, media, and telecom, consumer, and healthcare sectors.
Shujun Li
Boston: (617) 307.9293
ir@trustbridgepartners.com
In December 2015, Trustbridge Partners, along with Linear Capital Partners, Sparkland Ventures, and Danhua Capital, provided $17 million in Series A funding to Trustlook, a San Jose, CA-based mobile security provider for the Android platform.
In October 2016, Trustbridge Partners, along with Lilly Asia Ventures and Jiangsu Simcere Pharmaceutical, provided $30 million in Series B funding to Veritas Genetics, a Massachusetts-based biotech company that offers whole genome sequencing to consumers for under $1,000.